Sfoglia per Autore
The antiangiogenic effect of the metronomic combination of 5-Fluorouracil plus vinorelbine is mediated by FAK/AKT pathway downregulation and apoptosis activation
2020 Scagliotti, A; Grassilli, E; Cazzaniga, M; Capizzi, L; Lavitrano, M; Cerrito, M
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence
2020 Krasniqi, E; Pizzuti, L; Barchiesi, G; Sergi, D; Carpano, S; Botti, C; Kayal, R; Sanguineti, G; Marchetti, P; Botticelli, A; Marinelli, D; Gamucci, T; Natoli, C; Grassadonia, A; Tinari, N; Tomao, S; Tonini, G; Santini, D; Michelotti, A; Mentuccia, L; Vaccaro, A; Magnolfi, E; Gelibter, A; Magri, V; Cortesi, E; D'Onofrio, L; Cassano, A; Cazzaniga, M; Moscetti, L; Fabbri, A; Scinto, A; Corsi, D; Carbognin, L; Bria, E; La Verde, N; Garufi, C; Di Stefano, P; Mirabelli, R; Veltri, E; Paris, I; Giotta, F; Lorusso, V; Landucci, E; Ficorella, C; Roselli, M; Adamo, V; Ricciardi, G; Russo, A; Valerio, M; Berardi, R; Pistelli, M; Cannita, K; Zamagni, C; Garrone, O; Baldini, E; Livi, L; Meattini, I; Del Medico, P; Generali, D; De Maria, R; Risi, E; Ciliberto, G; Villa, A; Sperduti, I; Mazzotta, M; Barba, M; Giordano, A; Vici, P
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies
2020 Cazzaniga, M; Verusio, C; Ciccarese, M; Fumagalli, A; Sartori, D; Valerio, M; Airoldi, M; Moretti, G; Ficorella, C; Gianni, L; Michelotti, A; Zambelli, A; Febbraro, A; Generali, D; Pistelli, M; Garrone, O; Musolino, A; Vici, P; Maur, M; Mentuccia, L; La Verde, N; Bianchi, G; Artale, S; Blasi, L; De Laurentiis, M; Atzori, F; Turletti, A; Porpiglia, M; Santini, D; Fabi, A; Gebbia, V; Schirone, A; Palumbo, R; Ferzi, A; Frassoldati, A; Scavelli, C; Clivio, L; Giordano, M; Donadio, M; Biganzoli, L; Del Mastro, L; Bisagni, G; Livi, L; Natoli, C; Montemurro, F; Riccardi, F; Romagnoli, E; Marchetti, P; Torri, V; Pronzato, P; Mustacchi, G
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
2020 Bon, G; Pizzuti, L; Laquintana, V; Loria, R; Porru, M; Marchio, C; Krasniqi, E; Barba, M; Maugeri-Sacca, M; Gamucci, T; Berardi, R; Livi, L; Ficorella, C; Natoli, C; Cortesi, E; Generali, D; La Verde, N; Cassano, A; Bria, E; Moscetti, L; Michelotti, A; Adamo, V; Zamagni, C; Tonini, G; Barchiesi, G; Mazzotta, M; Marinelli, D; Tomao, S; Marchetti, P; Valerio, M; Mirabelli, R; Russo, A; Fabbri, M; D'Ostilio, N; Veltri, E; Corsi, D; Garrone, O; Paris, I; Sarobba, G; Giotta, F; Garufi, C; Cazzaniga, M; Del Medico, P; Roselli, M; Sanguineti, G; Sperduti, I; Sapino, A; De Maria, R; Leonetti, C; Di Leo, A; Ciliberto, G; Falcioni, R; Vici, P
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting
2020 Pizzuti, L; Krasniqi, E; Barchiesi, G; Della Giulia, M; Izzo, F; Sanguineti, G; Marchetti, P; Mazzotta, M; Giusti, R; Botticelli, A; Gamucci, T; Natoli, C; Grassadonia, A; Tinari, N; Iezzi, L; Tomao, S; Tomao, F; Tonini, G; Santini, D; Astone, A; Michelotti, A; De Angelis, C; Mentuccia, L; Vaccaro, A; Magnolfi, E; Gelibter, A; Magri, V; Cortesi, E; D'Onofrio, L; Cassano, A; Rossi, E; Cazzaniga, M; Moscetti, L; Omarini, C; Piacentini, F; Fabbri, M; Scinto, A; Corsi, D; Carbognin, L; Bria, E; La Verde, N; Samaritani, R; Garufi, C; Barni, S; Mirabelli, R; Sarmiento, R; Veltri, E; D'Auria, G; Paris, I; Giotta, F; Lorusso, V; Cardillo, F; Landucci, E; Mauri, M; Ficorella, C; Roselli, M; Adamo, V; Ricciardi, G; Russo, A; Berardi, R; Pistelli, M; Fiorio, E; Cannita, K; Sini, V; D'Ostilio, N; Foglietta, J; Greco, F; Zamagni, C; Garrone, O; Di Cocco, B; Baldini, E; Livi, L; Desideri, I; Meattini, I; Sarobba, G; Del Medico, P; De Tursi, M; Generali, D; De Maria, R; Risi, E; Ciliberto, G; Sperduti, I; Villa, A; Barba, M; Di Leo, A; Vici, P
Correction: NSABP FB-7: A phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer (Breast Cancer Research (2019) 21 (133) DOI: 10.1186/s13058-019-1196-y)
2020 Jacobs, S; Robidoux, A; Abraham, J; Pérez-Garcia, J; La Verde, N; Orcutt, J; Cazzaniga, M; Piette, F; Antolín, S; Aguirre, E; Cortes, J; Llombart-Cussac, A; Di Cosimo, S; Kim, R; Feng, H; Lipchik, C; Lucas, P; Srinivasan, A; Wang, Y; Song, N; Gavin, P; Balousek, A; Paik, S; Allegra, C; Wolmark, N; Pogue-Geile, K
Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success
2019 Cazzaniga, M; Danesi, R; Girmenia, C; Invernizzi, P; Elvevi, A; Uguccioni, M; Amaducci, L; Atzori, F; Blasi, L; Butti, C; Collova, E; De Conciliis, E; Fabi, A; Febbraro, A; Garrone, O; Gianni, L; Giotta, F; La Verde, N; Michelotti, A; Palumbo, R; Paris, I; Pistelli, M; Pizzuti, L; Rubino, D; Valerio, M; Zustovich, F
Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE
2019 Leo, S; Arnoldi, E; Repetto, L; Coccorullo, Z; Cinieri, S; Fedele, P; Cazzaniga, M; Lorusso, V; Latorre, A; Campanella, G; Ciccarese, M; Accettura, C; Pisconti, S; Rinaldi, A; Brunetti, C; Raffaele, M; Coltelli, L; Spazzapan, S; Fratino, L; Petrucelli, L; Biganzoli, L
Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project
2019 Cazzaniga, M; Munzone, E; Bocci, G; Afonso, N; Gomez, P; Langkjer, S; Petru, E; Pivot, X; Sanchez Rovira, P; Wysocki, P; Torri, V
NSABP FB-7: A phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer
2019 Jacobs, S; Robidoux, A; Abraham, J; Perez-Garcia, J; La Verde, N; Orcutt, J; Cazzaniga, M; Piette, F; Antolin, S; Aguirre, E; Cortes, J; Llombart-Cussac, A; Di Cosimo, S; Kim, R; Feng, H; Lipchik, C; Lucas, P; Srinivasan, A; Wang, Y; Song, N; Gavin, P; Balousek, A; Paik, S; Allegra, C; Wolmark, N; Pogue-Geile, K
Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours—the MACBETH project
2019 Cazzaniga, M; Ciruelos, E; Fabi, A; Garcia-Saenz, J; Lindman, H; Mavroudis, D; Schem, C; Steger, G; Timotheadou, E; Zaman, K; Torri, V
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience
2019 Pizzuti, L; Giordano, A; Michelotti, A; Mazzotta, M; Natoli, C; Gamucci, T; De Angelis, C; Landucci, E; Diodati, L; Iezzi, L; Mentuccia, L; Fabbri, A; Barba, M; Sanguineti, G; Marchetti, P; Tomao, S; Mariani, L; Paris, I; Lorusso, V; Vallarelli, S; Cassano, A; Airoldi, F; Orlandi, A; Moscetti, L; Sergi, D; Sarobba, M; Tonini, G; Santini, D; Sini, V; Veltri, E; Vaccaro, A; Ferrari, L; De Tursi, M; Tinari, N; Grassadonia, A; Greco, F; Botticelli, A; La Verde, N; Zamagni, C; Rubino, D; Cortesi, E; Magri, V; Pomati, G; Scagnoli, S; Capomolla, E; Kayal, R; Scinto, A; Corsi, D; Cazzaniga, M; Laudadio, L; Forciniti, S; Mancini, M; Carbognin, L; Seminara, P; Barni, S; Samaritani, R; Roselli, M; Portarena, I; Russo, A; Ficorella, C; Cannita, K; Carpano, S; Pistelli, M; Berardi, R; De Maria, R; Sperduti, I; Ciliberto, G; Vici, P
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study
2019 Cazzaniga, M; Pinotti, G; Montagna, E; Amoroso, D; Berardi, R; Butera, A; Cagossi, K; Cavanna, L; Ciccarese, M; Cinieri, S; Cretella, E; De Conciliis, E; Febbraro, A; Ferrau, F; Ferzi, A; Fiorentini, G; Fontana, A; Gambaro, A; Garrone, O; Gebbia, V; Generali, D; Gianni, L; Giovanardi, F; Grassadonia, A; Leonardi, V; Marchetti, P; Melegari, E; Musolino, A; Nicolini, M; Putzu, C; Riccardi, F; Santini, D; Saracchini, S; Sarobba, M; Schintu, M; Scognamiglio, G; Spadaro, P; Taverniti, C; Toniolo, D; Tralongo, P; Turletti, A; Valenza, R; Valerio, M; Vici, P; Clivio, L; Torri, V; Cicchiello, F; Riva, F; Vallini, I; Mazza, M; Bonfadini, C; Bordin, E; Canicatti, M; Cappuccio, F; Collova, E; De Angelis, C; Desorte, R; Donati, S; Drudi, G; Galanti, D; Mocerino, C; Orlando, L; Pellegrino, B; Pizzuti, L; Ridolfi, C; Rocca, A; Sarti, D; Spagnoletti, I; Tinari, N; Vandone, A; Vizzini, L
Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study
2019 Cosimo, S; Verde, N; Moretti, A; Cazzaniga, M; Generali, D; Bianchi, G; Mariani, L; Torri, V; Crippa, F; Paolini, B; Scaperrotta, G; De Santis, M; Nicola, M; Apolone, G; Gulino, A; Tripodo, C; Colombo, M; Folli, S; de Braud, F
Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?
2019 Cazzaniga, M; Biganzoli, L; Cortesi, L; De Placido, S; Donadio, M; Fabi, A; Ferro, A; Generali, D; Lorusso, V; Milani, A; Montagna, E; Munzone, E; Orlando, L; Pizzuti, L; Simoncini, E; Zamagni, C; Pappagallo, G
Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity
2019 Cavaletti, G; Cornblath, D; Merkies, I; Postma, T; Rossi, E; Alberti, P; Bruna, J; Argyriou, A; Briani, C; Velasco, R; Kalofonos, H; Psimaras, D; Ricard, D; Pace, A; Faber, C; Lalisang, R; Brandsma, D; Koeppen, S; Kerrigan, S; Schenone, A; Grisold, W; Mazzeo, A; Padua, L; Dorsey, S; Penas-Prado, M; Valsecchi, M; Bidoli, P; Cazzaniga, M
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study
2018 Cazzaniga, M; Verusio, C; Ciccarese, M; Fumagalli, A; Sartori, D; Ancona, C; Airoldi, M; Moretti, G; Ficorella, C; Arcangeli, V; Diodati, L; Zambelli, A; Febbraro, A; Generali, D; Pistelli, M; Garrone, O; Musolino, A; Vici, P; Maur, M; Mentuccia, L; La Verde, N; Bianchi, G; Artale, S; Blasi, L; Piezzo, M; Atzori, F; Turletti, A; Benedetto, C; Cursano, M; Fabi, A; Gebbia, V; Schirone, A; Palumbo, R; Ferzi, A; Frassoldati, A; Scavelli, C; Clivio, L; Torri, V; On behalf of The EVA Study, G
Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve
2018 Alberti, P; Rossi, E; Argyriou, A; Kalofonos, H; Briani, C; Cacciavillani, M; Campagnolo, M; Bruna, J; Velasco, R; Cazzaniga, M; Cortinovis, D; Valsecchi., M; Cavaletti, G
Erratum: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9 (31877-31887) DOI: 10.18632/oncotarget.25874)
2018 Cazzaniga, M; Verusio, C; Ciccarese, M; Fumagalli, A; Sartori, D; Valerio, M; Airoldi, M; Moretti, G; Ficorella, C; Arcangeli, V; Diodati, L; Zambelli, A; Febbraro, A; Generali, D; Pistelli, M; Garrone, O; Musolino, A; Vici, P; Maur, M; Mentuccia, L; La Verde, N; Bianchi, G; Artale, S; Blasi, L; Piezzo, M; Atzori, F; Turletti, A; Benedetto, C; Cursano, M; Fabi, A; Gebbia, V; Schirone, A; Palumbo, R; Ferzi, A; Frassoldati, A; Scavelli, C; Clivio, L; Torri, V
Treatment of advanced breast cancer with a metronomic schedule of oral vinorelbine: what is the opinion of Italian oncologists?
2018 Cazzaniga, M; Munzone, E; Montagna, E; Pappagallo, G
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile